BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain.
about
PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21Structural insights into the transcription-independent apoptotic pathway of p53PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosisThe DNA-binding domain mediates both nuclear and cytosolic functions of p53Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heartBcL-xL conformational changes upon fragment binding revealed by NMRSolution structure and binding specificity of the p63 DNA binding domainTGF-β induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid β plaques in Alzheimer's disease.Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax.Intermediate progenitors are increased by lengthening of the cell cycle through calcium signaling and p53 expression in human neural progenitorsHuman Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 proteinYin Yang 1 Promotes Thymocyte Survival by Downregulating p53.Increased resolution of aromatic cross peaks using alternate 13C labeling and TROSY.Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways.Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosisOrphan Nuclear Receptor NR4A1 Binds a Novel Protein Interaction Site on Anti-apoptotic B Cell Lymphoma Gene 2 Family Proteins.A conserved mechanism for binding of p53 DNA-binding domain and anti-apoptotic Bcl-2 family proteins.Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activityMany players in BCL-2 family affairs.Discoveries and controversies in BCL-2 protein-mediated apoptosis.Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xLA nanobody modulates the p53 transcriptional program without perturbing its functional architecturePart III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic metabolism.Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage.Direct induction of apoptosis using an optimal mitochondrially targeted p53.Ligand-independent antiapoptotic function of estrogen receptor-beta in lung cancer cellsStructural analysis of the interaction between Hsp90 and the tumor suppressor protein p53.Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death.Targeting the p53 pathway to protect the neonatal ischemic brain.Regulation of apoptosis by an intrinsically disordered region of Bcl-xL.Combretastatin A-4 induces p53 mitochondrial-relocalisation independent-apoptosis in non-small lung cancer cells.
P2860
Q24338602-238CFC84-32A6-4683-B8EA-7502F41A859DQ27004001-CA12ADD8-80B8-44AE-B7F1-7B79ED5C8A07Q27675952-2D7DBEB4-0252-46F8-95F1-618667A98826Q27683709-6D7228E7-6A94-4C51-8FE1-A50A074A33E7Q28244342-ECB911AF-672F-4F9D-A1A1-EDA747920975Q28533290-E9773B5C-40B5-42BD-A14D-FFC449065499Q28833410-FF708EEF-1B44-4559-B77F-C95738754273Q30498066-4840DFE9-CD1E-43E6-90F6-DEEC75DA5BCFQ34183833-2568CD97-C58B-4079-BD5E-7578911B6529Q35861867-005C4FA9-F74F-4851-A687-CDD2F17AD19AQ35974864-D8CDA049-95D2-4302-AC10-FBB5C0E0CE44Q36080596-A253395D-DB39-46ED-A57D-EC9A6C4D0F48Q36655752-24E14364-53E5-4478-BD64-589DA434BB83Q36663597-F12677BE-D9BC-4F05-BCD8-D26664E07370Q36666304-B1F83527-54DE-4A9A-B42F-6BF1FD24D181Q36855285-2DFC1B42-600D-4E89-8ABB-3FF9E5A174EFQ37065711-B5608BC5-4D78-4492-9661-EDF4D4D18CD2Q37671257-B82C26C4-84A5-440D-8597-E4A503875EE4Q37680206-06249A8A-1001-4960-BE04-B63EF3EB624EQ38185804-080C3AD7-B79A-433B-90AA-775D85F4210BQ38593940-E28C5728-B068-44BB-9572-AA6EAAF32D98Q38796648-2D141869-8E4B-4281-ABA6-F36700C461ABQ38946984-2CBAB78C-A43C-485E-9A66-AA6D89FB9C9EQ39226465-37A5D8AF-793E-40D7-9534-4C1453E97B80Q39331696-A5BCD414-A34E-44C4-84BF-8B9D43E1BC41Q39387682-D6F07F7E-4E08-422F-BCB5-E03E8C4D99F9Q39675651-7E0D205B-39C9-43F0-B6BD-6B3A0E2723CAQ41792117-0AC0568A-328C-4BAC-AEDA-8DFB434C9188Q46268031-F81D34FA-D7CE-4C85-803A-5DCB640297EBQ47301301-5A4A75C5-8977-4260-99E8-B8926FD1F0DEQ51864096-E9D44523-A7F9-4C0C-87CD-EB4EB80C872EQ53080449-1628D41C-5BB9-48E9-BD5E-EA8C4883D86BQ53085465-64DE7A61-90EB-4769-B970-14CB6E5D52C4
P2860
BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
BclxL changes conformation upo ...... mutant p53 DNA binding domain.
@ast
BclxL changes conformation upo ...... mutant p53 DNA binding domain.
@en
type
label
BclxL changes conformation upo ...... mutant p53 DNA binding domain.
@ast
BclxL changes conformation upo ...... mutant p53 DNA binding domain.
@en
prefLabel
BclxL changes conformation upo ...... mutant p53 DNA binding domain.
@ast
BclxL changes conformation upo ...... mutant p53 DNA binding domain.
@en
P2093
P2860
P356
P1476
BclxL changes conformation upo ...... mutant p53 DNA binding domain.
@en
P2093
Angelina Vaseva
Christian Klein
Franz Hagn
Horst Kessler
Natasha Marchenko
Oliver Demmer
Ute M Moll
P2860
P304
P356
10.1074/JBC.M109.065391
P407
P577
2009-12-02T00:00:00Z